A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice

Vaccine

Volumn 36, Issue 5, 2018, Pages 653-659

  Dai, Wenlong ^a,b   Zhang, Chao ^a,c   Zhang, Xueyang ^a,b   Xiong, Pei ^a,b   Liu, Qingwei ^a   Gong, Sitang ^c   Geng, Lanlan ^c   Zhou, Dongming ^a   Huang, Zhong ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Enterovirus D68; Vaccine; Virus like particle

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN VP0; PROTEIN VP1; PROTEIN VP3; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS LIKE PARTICLE VACCINE; CAPSID PROTEIN; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACULOVIRIDAE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; ENTEROVIRUS D68; ENTEROVIRUS INFECTION; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; MOUSE; NEWBORN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SUCKLING ANIMAL; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; ANIMAL; ENTEROVIRUS D; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; SERODIAGNOSIS; ULTRASTRUCTURE; VACCINE IMMUNOGENICITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; ENTEROVIRUS D, HUMAN; ENTEROVIRUS INFECTIONS; GENE EXPRESSION; HUMANS; IMMUNIZATION; IMMUNOGENICITY, VACCINE; MICE; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 85039748445     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.12.057     Document Type: Article

References (38)

1. Schieble, J.H., Fox, V.L., Lennette, E.H., A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 85 (1967), 297–310.
2. Khetsuriani, N., Lamonte-Fowlkes, A., Oberst, S., Pallansch, M.A., Enterovirus surveillance–United States, 1970–2005. MMWR Surveill Summ 55 (2006), 1–20.
3. Holm-Hansen, C.C., Midgley, S.E., Fischer, T.K., Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis 16 (2016), e64–e75.
4. Tokarz, R., Firth, C., Madhi, S.A., Howie, S.R., Wu, W., Sall, A.A., et al. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol 93 (2012), 1952–1958.
5. Wylie, T.N., Wylie, K.M., Buller, R.S., Cannella, M., Storch, G.A., Development and evaluation of an enterovirus D68 real-time reverse transcriptase PCR assay. J Clin Microbiol 53 (2015), 2641–2647.
6. Holm-Hansen, C.C., Midgley, S.E., Fischer, T.K., Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis, 2016.
7. Messacar, K., Robinson, C.C., Pretty, K., Yuan, J., Dominguez, S.R., Surveillance for enterovirus D68 in colorado children reveals continued circulation. J Clin Virol 92 (2017), 39–41.
8. Yip, C.C.Y., Lo, J.Y.C., Sridhar, S., Lung, D.C., Luk, S., Chan, K.H., et al. First report of a fatal case associated with EV-D68 infection in Hong Kong and emergence of an interclade recombinant in China revealed by genome analysis. Int J Mol Sci, 18, 2017.
9. Cabrerizo, M., Garcia-Iniguez, J.P., Munell, F., Amado, A., Madurga-Revilla, P., Rodrigo, C., et al. First cases of severe flaccid paralysis associated with enterovirus D68 infection in Spain, 2015–2016. Pediatr Infect Dis J, 2017.
10. Korematsu, S., Nagashima, K., Sato, Y., Nagao, M., Hasegawa, S., Nakamura, H., et al. “Spike” in acute asthma exacerbations during enterovirus D68 epidemic in Japan: a nation-wide survey. Allergol Int, 2017.
11. Stacpoole, S.R.L., Molyneux, A., Baumer, D., Acute segmental poliomyelitis-like flaccid paralysis in an adult in the UK, associated with enterovirus D68. Pract Neurol 17 (2017), 297–301.
12. Sejvar, J.J., Lopez, A.S., Cortese, M.M., Leshem, E., Pastula, D.M., Miller, L., et al. Acute flaccid myelitis in the United States, August-December 2014: results of nationwide surveillance. Clin Infect Dis 63 (2016), 737–745.
13. Messacar, K., Schreiner, T.L., Maloney, J.A., Wallace, A., Ludke, J., Oberste, M.S., et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 385 (2015), 1662–1671.
14. Aliabadi, N., Messacar, K., Pastula, D.M., Robinson, C.C., Leshem, E., Sejvar, J.J., et al. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 22 (2016), 1387–1394.
15. Greninger, A.L., Naccache, S.N., Messacar, K., Clayton, A., Yu, G., Somasekar, S., et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15 (2015), 671–682.
16. Fields, B.N., Knipe, D.M., Howley, P.M., Fields virology. 5th ed., 2007, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
17. Brown, B.A., Nix, W.A., Sheth, M., Frace, M., Oberste, M.S., Seven strains of enterovirus D68 detected in the United States during the 2014 severe respiratory disease outbreak. Genome Announc, 2, 2014.
18. Liu, Y., Sheng, J., Fokine, A., Meng, G., Shin, W.H., Long, F., et al. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 347 (2015), 71–74.
19. Lau, S.K., Yip, C.C., Zhao, P.S., Chow, W.N., To, K.K., Wu, A.K., et al. Enterovirus D68 infections associated with severe respiratory illness in elderly patients and emergence of a novel clade in Hong Kong. Sci Rep, 6, 2016, 25147.
20. Roldao, A., Mellado, M.C., Castilho, L.R., Carrondo, M.J., Alves, P.M., Virus-like particles in vaccine development. Expert Rev Vaccines 9 (2010), 1149–1176.
21. Kushnir, N., Streatfield, S.J., Yusibov, V., Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31 (2012), 58–83.
22. Liu, Q., Yan, K., Feng, Y., Huang, X., Ku, Z., Cai, Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30 (2012), 6642–6648.
23. Ku, Z., Liu, Q., Ye, X., Cai, Y., Wang, X., Shi, J., et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 32 (2014), 4296–4303.
24. Shen, C., Ku, Z., Zhou, Y., Li, D., Wang, L., Lan, K., et al. Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine 34 (2016), 4025–4031.
25. Zhang, C., Ku, Z., Liu, Q., Wang, X., Chen, T., Ye, X., et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 33 (2015), 2335–2341.
26. Zhang, C., Liu, Q., Ku, Z., Hu, Y., Ye, X., Zhang, Y., et al. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice. Antiviral Res 129 (2016), 47–51.
27. Zhou, Y., Shen, C., Zhang, C., Zhang, W., Wang, L., Lan, K., et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res 132 (2016), 165–169.
28. Chung, Y.C., Ho, M.S., Wu, J.C., Chen, W.J., Huang, J.H., Chou, S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26 (2008), 1855–1862.
29. Li, H.Y., Han, J.F., Qin, C.F., Chen, R., Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31 (2013), 3281–3287.
30. Zhao, H., Li, H.Y., Han, J.F., Deng, Y.Q., Li, Y.X., Zhu, S.Y., et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 97 (2013), 10445–10452.
31. Ku, Z., Shi, J., Liu, Q., Huang, Z., Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J Virol Methods 186 (2012), 193–197.
32. Cai, Y., Liu, Q., Huang, X., Li, D., Ku, Z., Zhang, Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 31 (2013), 2215–2221.
33. Shen, C., Liu, Q., Zhou, Y., Ku, Z., Wang, L., Lan, K., et al. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine 34 (2016), 5005–5012.
34. Reed, L.J., Muench, H., A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27 (1938), 493–497.
35. Liu, Q., Ku, Z., Cai, Y., Sun, B., Leng, Q., Huang, Z., Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 173 (2011), 115–120.
36. Ku, Z., Ye, X., Huang, X., Cai, Y., Liu, Q., Li, Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One, 8, 2013, e57601.
37. Chung, Y.C., Huang, J.H., Lai, C.W., Sheng, H.C., Shih, S.R., Ho, M.S., et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12 (2006), 921–927.
38. Brautigam, S., Snezhkov, E., Bishop, D.H., Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 192 (1993), 512–524.